NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases<
24 May 2024

Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases

Committed to restoring brain function to enable a better life for people with schizophrenia
LAVA provides business updates and reports first quarter 2024 financial results<
21 May 2024

LAVA provides business updates and reports first quarter 2024 financial results

Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update<
14 May 2024

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update<
09 May 2024

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights<
09 May 2024

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions
Memo Therapeutics increases Series C financing to CHF 45 million<
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing investors.
Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting<
15 Apr 2024

Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting

NRTX-1001 administration has been well-tolerated in all individuals treated to date
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update<
29 Mar 2024

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights<
27 Mar 2024

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDA
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update<
21 Mar 2024

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mineralys Therapeutics 4Q and Full Year 2023 Financial Results

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.